Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Inex Pharmaceuticals Provides Progress Update on Alnylam Collaboration
May 1st, 2007
Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) reported that one of its collaboration partners, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), announced that it will advance a systemically delivered RNA interference (RNAi) therapeutic, ALN-VSP01, for the treatment of liver cancer and potentially other solid tumors. The announcement was made at the American Association for Cancer Research (AACR) Annual Meeting being held in Los Angeles, California. The complete details of Alnylam's announcement can be accessed from Alnylam's website at www.alnylam.com. ALN-VSP01 is a lipid-based formulation of two small interfering RNAs, or siRNAs, the molecules that mediate RNAi....
Source: Cancer Weekly (2007-05-01)
|
